Inhibikase Therapeutics (IKT) Shares Outstanding (2020 - 2026)
Inhibikase Therapeutics (IKT) posted quarterly Shares Outstanding (Entity) of $172.3 million for Q1 2026, up 131.78% year-over-year from $74.3 million in Q1 2025, and up 75.27% quarter-over-quarter from $98.3 million in Q4 2025.
Inhibikase Therapeutics (IKT) Shares Outstanding (2020 - 2026) Analysis & Trends
Inhibikase Therapeutics (IKT) has reported Shares Outstanding (Entity) for 7 consecutive years, with $172.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 131.78% year-over-year to $172.3 million; the TTM figure through Mar 2026 stood at $172.3 million (up 131.78% YoY), while the FY2025 annual figure was $98.3 million, up 314.6% from the prior year.
- Shares Outstanding (Entity) grew to $172.3 million in Q1 2026 per IKT's latest filing, from $98.3 million in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $172.3 million in Q1 2026 and bottomed at $4.2 million in Q1 2022.
- Historically, Shares Outstanding (Entity) has averaged $34.0 million across 5 years, with a median of $6.5 million in 2024.
- Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) gained 0.29% — and 2025, when it surged 1047.81%.
- Inhibikase Therapeutics' Shares Outstanding (Entity) stood at $4.2 million in 2022, then surged by 47.13% to $6.2 million in 2023, then surged by 283.3% to $23.7 million in 2024, then jumped by 314.6% to $98.3 million in 2025, then soared by 75.27% to $172.3 million in 2026.
- Business Quant data shows IKT's Shares Outstanding (Entity) at $172.3 million in Q1 2026, $98.3 million in Q4 2025, and $74.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 62.19 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 210.89 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.45 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.05 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 445.06 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 133.61 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Inhibikase Therapeutics | 420.72 Mn | 261.70 Mn | - | 174.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 174.57 Mn |
| Mar 31, 2026 | 172.31 Mn |
| Dec 31, 2025 | 98.31 Mn |
| Sep 30, 2025 | 90.05 Mn |
| Jun 30, 2025 | 90.01 Mn |
| Mar 31, 2025 | 89.54 Mn |
| Dec 31, 2024 | 23.71 Mn |
| Sep 30, 2024 | 8.88 Mn |
| Jun 30, 2024 | 7.54 Mn |
| Mar 31, 2024 | 6.34 Mn |
| Dec 31, 2023 | 5.33 Mn |
| Sep 30, 2023 | 5.34 Mn |
| Jun 30, 2023 | 5.23 Mn |
| Mar 31, 2023 | 4.59 Mn |
| Dec 31, 2022 | 4.20 Mn |
| Sep 30, 2022 | 4.20 Mn |
| Jun 30, 2022 | 4.20 Mn |
| Mar 31, 2022 | 4.20 Mn |
| Dec 31, 2021 | 3.03 Mn |
| Sep 30, 2021 | 4.19 Mn |